Arcus Biosciences (RCUS) Operating Leases (2020 - 2022)

Arcus Biosciences' Operating Leases history runs 3 years deep, the most recent figure standing at $119.2 million for Q3 2022.

• In Q3 2022, Operating Leases rose 130.55% year-over-year to $119.2 million; the TTM figure through Sep 2022 stood at $119.2 million (up 130.55% YoY), while the FY2021 annual figure was $116.9 million, up 666.82% from the prior year.
• Operating Leases for Q3 2022 stood at $119.2 million, down from $121.3 million in the prior quarter.
• The five-year high for Operating Leases was $121.3 million in Q2 2022, with the low at $14.7 million in Q1 2021.
• The 3-year median for Operating Leases is $83.5 million (2021), against an average of $75.8 million.
• Peak annual rise in Operating Leases reached 680.74% in 2022, while the deepest fall reached 130.55% in 2022.
• Arcus Biosciences' Operating Leases stood at $15.2 million in 2020, then soared by 666.82% to $116.9 million in 2021, then grew by 1.97% to $119.2 million in 2022.
• Business Quant data shows RCUS's Operating Leases at $119.2 million in Q3 2022, $121.3 million in Q2 2022, and $114.8 million in Q1 2022.